(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦36Â÷ Ãá°èÇмú´ëȸ : 2021-04-17 |
|
(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦36Â÷ Ãá°èÇмú´ëȸ : 2021-04-17 ±³À°ÀÏÀÚ : 2021-04-17 ±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À° ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦36Â÷ Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ ´ã´çÀÚ : ÇѼ¼¹Ì ¿¬¶ôó : 02-512-0044 À̸ÞÀÏ : office@sgo.or.kr ±³À°Á¾·ù : »êºÎÀΰú Âü¼®¿¹»óÀοø : 300¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ ¼¼ºÎ¼ö°·á : 60,000¿ø ºñ°í Àü¹®ÀÇ 60,000Àü°øÀÇ 45,000ÀϹÝÀÇ,¿¬±¸¿ø,°£È£»ç 30,000 65¼¼ÀÌ»ó ¹«·á ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±âŸ 04-17 Channel 1 & 2 09:00~09:10 Opening Remarks ±è¿µÅÂ(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå) ±³À°½Ã°£ 04-17 Channel 1 & 2 09:10~09:30 Impact of COVID-19 on the care of gynecologic cancer patients requiring surgery Sudha Sundar(Univ. of Birmingham UK) ±³À°½Ã°£ 04-17 Channel 1 & 2 09:30~09:35 Designated discussion ±Çº´¼ö(°æÈñÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 09:35~09:45 COVID-19 ´ëÀ¯Çà°ú ¾ÏȯÀÚ Ä¡·á, ÀÓ»ó½ÃÇè ¹× ¹é½Å Á¢Á¾ ¹Ú¼öÁø(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 09:45~09:50 Designated discussion ¹Î°æÁø(°í·ÁÀÇ´ë) Åä·Ð 04-17 Channel 1 & 2 09:50~10:00 Discussion () ±³À°½Ã°£ 04-17 Channel 1 & 2 10:00~10:15 Surgical quality of ovarian cancer: how to evaluate and improve? Àå¼®ÁØ(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 10:15~10:30 Designated discussion À̼ºÁ¾À̽ÅÈÀÌÀºÁÖ(°¡Å縯ÀÇ´ë¿ï»êÀÇ´ëÁß¾ÓÀÇ´ë) ÈÞ½Ä 04-17 Channel 1 & 2 10:30~10:50 Break Time () ±³À°½Ã°£ 04-17 Channel 1 & 2 10:50~11:00 Drug repositioning for ovarian cancer targeting mevalonate pathway Yusuke Kobayashi(Keio Univ. Japan) ±³À°½Ã°£ 04-17 Channel 1 & 2 11:00~11:10 Novel nanomedicine for epithelial ovarian cancer : cathepsin B-cleavable peptide-conjugated doxorubicin prodrug Á¤¼ö¿µ(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 11:10~11:20 Multi-Omics and Therapeutically Applicable Research of Ovarian Cancer Gang Chen(Tongji Medical College China) ±³À°½Ã°£ 04-17 Channel 1 & 2 11:20~11:30 Designated discussion ³²ÀºÁö(¿¬¼¼ÀÇ´ë) Åä·Ð 04-17 Channel 1 & 2 11:30~11:35 Discussion () ±³À°½Ã°£ 04-17 Channel 1 & 2 11:35~11:45 Risk of adverse obstetric outcomes in patients with a history of endometrial cancer: a population-based cohort study ½É½ÂÇõ(°Ç±¹ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 11:45~11:55 Comparisons of survival between bevacizumab vs. olaparib in platinum-sensitive, relapsed ovarian cancer (KGOG 3052) ±è¼¼ÀÍ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 11:55~12:05 A computational model for identification of parametrial invasion in women with early-stage cervical cancer Kittipat Charoenkwan(Chiang Mai Univ. Thailand) ±³À°½Ã°£ 04-17 Channel 1 & 2 12:05~12:15 Designated discussion ¼Û¿ëÁß(ºÎ»êÀÇ´ë) Åä·Ð 04-17 Channel 1 & 2 12:15~12:20 Discussion () ±³À°½Ã°£ 04-17 Channel 1 12:20~12:40 PARP inhibitors for advanced or recurrent ovarian cancer B. Monk(Univ. of Arizona USA) ±³À°½Ã°£ 04-17 Channel 1 12:40~13:00 PBM in patients with gynecologic cancer ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 04-17 Channel 2 12:20~12:40 Lenvatinib plus pembrolizumab for recurrent endometrial cancer ±è±âµ¿(¼¿ïÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 2 12:40~13:00 Time to Navigate Patient Journey with Optimal Front-line Treatment in Advanced Ovarian Cancer ÀÌÁ¤¿ø(¼º±Õ°üÀÇ´ë) ½Ä»ç 04-17 Channel 1 & 2 13:00~14:00 Lunch () ±³À°½Ã°£ 04-17 Channel 1 14:00~14:07 Immunohistochemical and genetic characteristics of invasive stratified mucin-producing carcinoma of the uterine cervix ¹ÚÀºÇâ(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 14:07~14:14 Circulating tumor cells as a predictive marker for treatment monitoring of ovarian cancer patients. À̽¹Ì(°è¸íÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 14:14~14:21 C-peptide prevents hyperglycemia-induced TGase2 activation in ovarian cancer cells ¿À¿µÅÃ(°¿øÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 14:21~14:30 Distillation È«ÁøÈ(°í·ÁÀÇ´ë) Åä·Ð 04-17 Channel 1 14:30~14:40 Discussion () ±³À°½Ã°£ 04-17 Channel 1 14:40~14:47 Accuracy of HPV tests on urine versus clinician-collected samples for the detection of cervical precancer: meta-analysis Á¶Çö¿õ(°í·ÁÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 14:47~14:54 Dynamics of Fecal Microbiota with and without Invasive Cervical Cancer and Its Application in Early Diagnosis ÀÌÀ±Èñ(°æºÏÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 14:54~15:01 Concerns for a long lead time on confirmatory test after abnormal Pap test in the COVID-19 era ±è¹Ì¼±(Â÷ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 15:01~15:10 Distillation ±è¹Ì°æ(ÀÌÈÀÇ´ë) Åä·Ð 04-17 Channel 1 15:10~15:20 Discussion () ±³À°½Ã°£ 04-17 Channel 1 15:20~15:27 Determining the extent of lymphadenectomy in patients with endometrial cancer ½Å¿ø±³(±¹¸³¾Ï¼¾ÅÍ) ±³À°½Ã°£ 04-17 Channel 1 15:27~15:34 Nomogram for microscopic lymph node metastasis in surgically staged endometrioid endometrial cancer patients °øÅ¿í(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 15:34~15:41 Incidence and risk factors of VTE in patients with cervical cancer using the Korean national health insurance data À̹æÇö(ÀÎÇÏÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 15:41~15:48 Survival analysis of chemoradiotherapy versus chemotherapy alone for stage III endometrial cancer: a multicenter study À¯Áö±Ù(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 15:48~16:00 Distillation ÃÖ¹Îö(Â÷ÀÇ´ë) Åä·Ð 04-17 Channel 1 16:00~16:10 Discussion () ÈÞ½Ä 04-17 Channel 1 16:10~16:20 Break Time () ±³À°½Ã°£ 04-17 Channel 2 14:00~14:10 WHO classification of female genital tumors, the 5th ed. ÀÌö(¼¿ïÀÇ´ë º´¸®°ú) ±³À°½Ã°£ 04-17 Channel 2 14:10~14:20 ESMO-ESGO new guideline for endometrial cancer: focusing on molecular classifier Á¶ÇѺ°(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 2 14:20~14:40 Panel discussion ±è¹Î±ÔÀ̸¶¸®¾ÆÀÌÁ¤À½(¼º±Õ°üÀÇ´ë ¼¿ïÀÇ´ë °¡Å縯ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 2 14:40~14:50 Adjuvant therapy for postoperative cervical cancer ±è¿ë¹è(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇÐÈ) ±³À°½Ã°£ 04-17 Channel 2 14:50~15:00 Intraoperative detection of lymph node metastasis: ÁÖ¿ø´ö(Â÷ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 2 15:00~15:20 Panel discussion ½Å¼ÒÁøÀÓ°¡¿ø¹®ÀçÈñ(°è¸íÀǴ뵿±¹ÀǴ뼿ïÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 2 15:20~15:30 Immune checkpoint inhibitors in recurrent ½É½ÂÇõ(°Ç±¹ÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 2 15:30~15:40 Candidate biomarkers for immune checkpoint inhibitors È«¼÷Èñ(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú) ±³À°½Ã°£ 04-17 Channel 2 15:40~16:00 Panel discussion ³ëÁÖ¿ø¹®¿ëÈÀ¯ÇåÁ¾(Â÷ÀÇ´ë Â÷ÀÇ´ë Ç÷¾×Á¾¾ç³»°ú Ãæ³²ÀÇ´ë) ÈÞ½Ä 04-17 Channel 2 16:00~16:20 Break Time () ±³À°½Ã°£ 04-17 Channel 1 & 2 16:20~16:35 Case presentation & voting management ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04-17 Channel 1 & 2 16:35~16:50 Panel discussion ¹ÚÁ¤¿¹èÀ縸ȫ´ë±â(¿ï»êÀÇ´ëÇѾçÀÇ´ë°æºÏÀÇ´ë) ±âŸ 04-17 Channel 1 & 2 16:50~17:00 ½Ådzȣ¿ùÇмú»ó ¹× JGO Best Reviewer Award ¼ö»óÀÚ ¹ßÇ¥ () ±âŸ 04-17 Channel 1 & 2 17:00~17:10 Closing Remarks () |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|